Actinium Pharmaceuticals, Inc. Income Statement
ATNM|6 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$90,000
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$36M
FY2025
Net Income
-$34M
FY2025
Actinium Pharmaceuticals, Inc. reported $90,000 in revenue and $34M in net loss for FY2025. Revenue has declined at a 47.0% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2011 |
|---|---|---|---|---|---|---|
| Revenue | $90.0K | $81.0K | $1.0M | $1.1M | $1.1M | $0 |
| Cost of Revenue | - | - | - | - | $900.0K | $0 |
| Gross Profit | - | - | - | - | - | $0 |
| SG&A Expense | $15.2M | $13.3M | $12.0M | $8.1M | $6.3M | $3.0M |
| R&D Expense | $21.1M | $38.7M | $23.1M | $18.0M | $16.1M | $323.8K |
| Operating Income | -$36.2M | -$51.9M | -$34.1M | -$25.0M | -$22.4M | -$3.3M |
| Interest Expense | - | - | $1.1M | $190.0K | $178.0K | -$175.1K |
| Income Tax | - | - | - | - | - | $0 |
| Net Income | -$33.9M | -$48.8M | -$33.0M | -$24.8M | -$22.2M | -$3.4M |
| EPS (Basic) | -$1.27 | -$1.83 | -$1.37 | -$1.20 | - | - |
| EPS (Diluted) | -$1.27 | -$1.83 | -$1.37 | -$1.20 | -$1.83 | $0.01 |
| Shares Outstanding | 31.2M | 27.6M | 25.7M | 22.1M | 17.5M | 11.2M |
| Operating Margin | -40274.4% | -64098.8% | -3311.1% | -2182.2% | -1957.4% | - |
| Profit Margin | -37652.2% | -60269.1% | -3205.5% | -2165.6% | -1941.9% | - |